NCT04108039View on ClinicalTrials.gov

Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

January 15, 2022

Study Completion Date

May 15, 2022

Conditions
InfertilityIVFPreimplantation Diagnosis
Interventions
DRUG

GnRh antagonist

In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS

DRUG

Micronized progesterone

Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.

Trial Locations (1)

08028

Institut Universitari Dexeus, Barcelona

All Listed Sponsors
lead

Fundacion Dexeus

OTHER

NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. | Biotech Hunter | Biotech Hunter